PROTAC HK2 Degrader-1

Overview

PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine ( HY-B0486 ) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide ( HY-14658 ) as a CRBN ligand-linked PROTAC . PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research. (Pink: Hexokinase 2 ligand ( HY-B0486 ); Blue: Cereblon ligand ( HY-103596 ); Black: linker).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Hexokinase

Product Information

• Catalog No.: HY-155008
• CAS No.: 3033812-84-6
• Molecular Formula: C32H28Cl2N6O5
• Molecular Weight: 647.51
• Purity: 99.76%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 1.3 mg/mL (2.01 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source